Organon & Co. reported $6.13B of revenue over the trailing twelve months, −2.5% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $6.13B (to Q2 2026). Net income: $209M, trailing twelve months to Q2 2026. Free cash flow: $567M, trailing twelve months to Q2 2026. EPS: $0.78, trailing twelve months to Q2 2026.

OGNOrganon & Co.

Healthcare

$13.81+33% 1Y

$13.81

$5.6952 weeks$13.81

Latest close: a new 52-week highOct 9, 2026what changed →

OGN as reported

Organon & Co. reported $6.13B of revenue over the trailing twelve months, −2.5% on the year before. 9 reported series are charted on this page, each one as filed.

$6.13B

Revenue, trailing twelve months · to Q2 2026 · −2.5% against the twelve months before

Net income: $209M
Net income · −70% year on year · trailing twelve months to Q2 2026
Free cash flow: $567M
Free cash flow · −14% year on year · trailing twelve months to Q2 2026
EPS: $0.78
EPS · −71% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for OGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$6.13B	−2.5%	Q2 2026
Net income	$209M	−70%	Q2 2026
EPS	$0.78	−71%	Q2 2026
Gross margin	53%	n/a	Q2 2026
Net margin	3.3%	n/a	Q2 2026
ROE	32%	n/a	Q2 2026
ROA	2.2%	n/a	Q2 2026
Free cash flow	$567M	−14%	Q2 2026
P/E	17.7	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.